company background image
TARA

Protara Therapeutics NasdaqGM:TARA Stock Report

Last Price

US$3.66

Market Cap

US$41.2m

7D

1.1%

1Y

-41.8%

Updated

04 Dec, 2022

Data

Company Financials +
TARA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

TARA Stock Overview

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases.

Protara Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Protara Therapeutics
Historical stock prices
Current Share PriceUS$3.66
52 Week HighUS$7.16
52 Week LowUS$2.38
Beta1.44
1 Month Change28.87%
3 Month Change13.31%
1 Year Change-41.81%
3 Year Changen/a
5 Year Changen/a
Change since IPO-87.80%

Recent News & Updates

The Prognosis For Protara Therapeutics

Oct 13

Here's Why We're Not Too Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

Sep 12
Here's Why We're Not Too Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

Recent updates

Here's Why We're Not Too Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

Sep 12
Here's Why We're Not Too Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?

Mar 21
Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?

Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Deliver On Growth Plans?

Dec 06
Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Deliver On Growth Plans?

Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?

Aug 17
Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?

What Type Of Shareholders Make Up Protara Therapeutics, Inc.'s (NASDAQ:TARA) Share Registry?

Mar 08
What Type Of Shareholders Make Up Protara Therapeutics, Inc.'s (NASDAQ:TARA) Share Registry?

How Many Protara Therapeutics, Inc. (NASDAQ:TARA) Shares Have Insiders Sold, In The Last Year?

Jan 12
How Many Protara Therapeutics, Inc. (NASDAQ:TARA) Shares Have Insiders Sold, In The Last Year?

Shareholder Returns

TARAUS BiotechsUS Market
7D1.1%4.2%1.5%
1Y-41.8%-7.4%-14.9%

Return vs Industry: TARA underperformed the US Biotechs industry which returned -7.4% over the past year.

Return vs Market: TARA underperformed the US Market which returned -14.9% over the past year.

Price Volatility

Is TARA's price volatile compared to industry and market?
TARA volatility
TARA Average Weekly Movement11.2%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: TARA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: TARA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a31Jesse Sheffermanhttps://www.protaratx.com

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease.

Protara Therapeutics, Inc. Fundamentals Summary

How do Protara Therapeutics's earnings and revenue compare to its market cap?
TARA fundamental statistics
Market CapUS$41.24m
Earnings (TTM)-US$37.21m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TARA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$37.21m
Earnings-US$37.21m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.30
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did TARA perform over the long term?

See historical performance and comparison